IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that Health Canada has issued a medical device licence for the Company's IMRX system permitting IMRIS to market its newest products, IMRISNV and IMRIScardio in Canada.
IMRISNV and IMRIScardio are the first systems in the world to allow the capabilities of both MRI and x-ray angiography in a single suite without the need to transport the patient between modalities.
Neurovascular diseases including acute ischemic stroke require rapid assessment and treatment. IMRISNV features a wide bore 3T MRI scanner and a bi-plane angiography system completely integrated into a single suite that permits the patient to transition quickly and seamlessly between MR imaging and intervention without transporting the patient between modalities. Using IMRISNV, MR images can be taken before and during procedures to assess tissue health, and can also be used in conjunction with the fluoroscopic images during the interventional procedure. On completion of the procedure, new images can be taken to evaluate the intervention.
Cardiovascular interventions demand a high level of accuracy in the diagnosis of patients and in the assessment of treatments. IMRIScardio provides physicians with enhanced images for visualizing the cardiovascular system before, during and after an intervention. The IMRIScardio suite includes a wide bore 1.5T MRI scanner and a single-plane or bi-plane angiography system providing the ability to alternate between imaging modalities and immediately assess treatment.
IMRISNV and IMRIScardio are available in multiple room configurations to provide diagnostic, interventional and surgical capabilities, which significantly enhance the utilization of equipment and space for hospitals. Earlier this year, IMRISNV and IMRIScardio were approved for sale in the United States and Europe.
Camouflage detection boosts neural networks for brain tumor diagnosis